Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), relating to its proposed merger with GRI Bio, Inc. Under the terms of the agreement, VLON shareholders are expected to own approximately 17% of the combined company.
Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), relating to its proposed merger with GRI Bio, Inc. Under the terms of the agreement, VLON shareholders are expected to own approximately 17% of the combined company.